vs
Side-by-side financial comparison of Actinium Pharmaceuticals, Inc. (ATNM) and CytoMed Therapeutics Ltd (GDTC). Click either name above to swap in a different company.
CytoMed Therapeutics Ltd is the larger business by last-quarter revenue ($115.4K vs $90.0K, roughly 1.3× Actinium Pharmaceuticals, Inc.).
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing targeted radiotherapies for oncology patients with unmet medical needs, covering hematologic cancers and solid tumors. Its pipeline uses antibody radiation conjugate technology to deliver precise cancer treatment while minimizing harm to healthy tissue.
CytoMed Therapeutics Ltd is a clinical-stage biopharmaceutical company focused on developing innovative allogeneic chimeric antigen receptor (CAR-T) cell therapies for treating hematological malignancies and solid tumors. It primarily serves global oncology patient populations and advances candidates targeting unmet medical needs in the immuno-oncology segment.
ATNM vs GDTC — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $90.0K | $115.4K |
| Net Profit | $-5.1M | — |
| Gross Margin | — | — |
| Operating Margin | -6324.4% | — |
| Net Margin | -5701.1% | — |
| Revenue YoY | — | — |
| Net Profit YoY | 55.6% | — |
| EPS (diluted) | $-0.16 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $90.0K | — | ||
| Q2 25 | — | $115.4K | ||
| Q1 24 | $927.0K | — | ||
| Q4 23 | $1.0M | — | ||
| Q3 23 | $1.1M | — | ||
| Q2 23 | $461.0K | — | ||
| Q1 23 | $547.0K | — | ||
| Q4 22 | $0 | — |
| Q3 25 | $-5.1M | — | ||
| Q2 25 | — | — | ||
| Q1 24 | $-8.7M | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $-13.3M | — | ||
| Q2 23 | $-15.2M | — | ||
| Q1 23 | $-11.0M | — | ||
| Q4 22 | $-10.6M | — |
| Q3 25 | -6324.4% | — | ||
| Q2 25 | — | — | ||
| Q1 24 | -1035.3% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -1335.0% | — | ||
| Q2 23 | -3393.1% | — | ||
| Q1 23 | -2117.7% | — | ||
| Q4 22 | — | — |
| Q3 25 | -5701.1% | — | ||
| Q2 25 | — | — | ||
| Q1 24 | -935.3% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -1235.0% | — | ||
| Q2 23 | -3293.1% | — | ||
| Q1 23 | -2017.7% | — | ||
| Q4 22 | — | — |
| Q3 25 | $-0.16 | — | ||
| Q2 25 | — | — | ||
| Q1 24 | $-0.31 | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $-0.49 | — | ||
| Q2 23 | $-0.58 | — | ||
| Q1 23 | $-0.43 | — | ||
| Q4 22 | $-0.43 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.4M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $13.8M | — |
| Total Assets | $56.2M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $53.4M | — | ||
| Q2 25 | — | — | ||
| Q1 24 | $84.1M | — | ||
| Q4 23 | $76.7M | — | ||
| Q3 23 | $83.0M | — | ||
| Q2 23 | $91.3M | — | ||
| Q1 23 | $94.5M | — | ||
| Q4 22 | $108.9M | — |
| Q3 25 | $13.8M | — | ||
| Q2 25 | — | — | ||
| Q1 24 | $43.9M | — | ||
| Q4 23 | $36.4M | — | ||
| Q3 23 | $43.6M | — | ||
| Q2 23 | $53.1M | — | ||
| Q1 23 | $57.2M | — | ||
| Q4 22 | $66.5M | — |
| Q3 25 | $56.2M | — | ||
| Q2 25 | — | — | ||
| Q1 24 | $88.4M | — | ||
| Q4 23 | $81.4M | — | ||
| Q3 23 | $88.9M | — | ||
| Q2 23 | $99.1M | — | ||
| Q1 23 | $102.0M | — | ||
| Q4 22 | $114.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-855.3K |
| Free Cash FlowOCF − Capex | — | $-855.4K |
| FCF MarginFCF / Revenue | — | -741.5% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-6.3M | — | ||
| Q2 25 | — | $-855.3K | ||
| Q1 24 | $-7.4M | — | ||
| Q4 23 | $-47.3M | — | ||
| Q3 23 | $-11.1M | — | ||
| Q2 23 | $-13.6M | — | ||
| Q1 23 | $-15.1M | — | ||
| Q4 22 | $-7.8M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | $-855.4K | ||
| Q1 24 | $-7.4M | — | ||
| Q4 23 | $-47.5M | — | ||
| Q3 23 | $-11.2M | — | ||
| Q2 23 | $-13.7M | — | ||
| Q1 23 | $-15.2M | — | ||
| Q4 22 | $-7.8M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | -741.5% | ||
| Q1 24 | -796.7% | — | ||
| Q4 23 | -4660.3% | — | ||
| Q3 23 | -1037.7% | — | ||
| Q2 23 | -2969.6% | — | ||
| Q1 23 | -2770.2% | — | ||
| Q4 22 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | 0.0% | ||
| Q1 24 | 1.2% | — | ||
| Q4 23 | 15.0% | — | ||
| Q3 23 | 2.8% | — | ||
| Q2 23 | 10.2% | — | ||
| Q1 23 | 13.9% | — | ||
| Q4 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
